With Novartis, ImmunoGen Adds $45 Mil. And Another Licensor For Its Antibody-Drug Conjugate Platform
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal gives Novartis access to develop therapeutics against an unspecified number of targets, while ImmunoGen gets more good news on top of positive Phase II data for its lead candidate.
You may also be interested in...
Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.
Antibody-Drug Conjugates: The Next Generation Of Moving Parts
The next generation of antibody-drug conjugates have much room for improvement: engineered proteins, drugs, the linkers that bond them together, and perhaps even new targets to attack. All their complexity is an invitation to innovation, but will the parts come together into products that prove safe and efficacious in the clinic?
ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie
The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.